Fresenius Kabi Launches Dalbavancin Injection for Single-Dose Regimen Use

Updated: November 24, 2025 20:00

Image Source : The Joplin Globe

Fresenius Kabi has introduced Dalbavancin for injection, approved exclusively for a single-dose regimen. This antibiotic addresses acute bacterial skin and skin structure infections (ABSSSI), offering a simplified treatment with proven comparable efficacy and safety to multi-dose therapies.

Fresenius Kabi has announced the launch of Dalbavancin, a novel antibiotic injection designed for single-dose use, aimed at treating severe bacterial skin infections. Dalbavancin’s introduction provides clinicians with an effective therapeutic option that reduces treatment complexity, potentially improving patient compliance and outcomes.

The drug is available in 500 mg vials and has secured regulatory approvals for single-dose administration only, a regimen supported by clinical trials demonstrating noninferior efficacy compared to traditional two-dose regimens. Dalbavancin’s long half-life facilitates effective bacterial eradication with a single intravenous infusion administered over approximately 30 minutes.

Clinical evidence shows that Dalbavancin not only ensures similar safety and success rates as multi-dose treatments but also reduces hospital stays and associated costs by facilitating earlier patient discharge. This aligns with global trends favoring treatments that simplify antibiotic administration while maintaining high efficacy, particularly important for managing acute bacterial skin and skin structure infections (ABSSSI).

Fresenius Kabi’s move to market Dalbavancin reflects its commitment to innovative solutions in infectious disease care, helping address healthcare delivery challenges and enhancing patient convenience.

Key Highlights:

Dalbavancin injection launched for single-dose regimen use only, available in 500 mg vials.
Approved for treatment of acute bacterial skin and skin structure infections (ABSSSI).
Clinical trials confirm efficacy and safety comparable to two-dose regimens.
Single infusion lasting about 30 minutes improves patient compliance and reduces hospital stays.
Supports early discharge and cost-effective care delivery in bacterial infection management.
Strengthens Fresenius Kabi’s portfolio in innovative antibiotics and patient-centric therapies.

Sources: Fresenius Kabi official announcements, FDA approvals, clinical trial data, PubMed studies

Stay Ahead – Explore Now! Azad Engineering’s Game-Changing Deal with Pratt & Whitney Canada Elevates India’s Aerospace Ambitions